arlocabtagene autoleucel (BMS-986393) / BMS 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
arlocabtagene autoleucel (BMS-986393) / BMS
QUINTESSENTIAL-2, NCT06615479: A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma

Recruiting
3
440
Europe, Canada, Japan, US, RoW
BMS-986393, Cyclophosphamide, Fludarabine, Daratumumab, Pomalidomide, Dexamethasone, Carfilzomib
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, Celgene Corporation
Relapsed or Refractory Multiple Myeloma (RRMM)
12/27
07/32
QUINTESSENTIAL, NCT06297226: Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

Recruiting
2
175
Canada, Japan, US, RoW
Arlocabtagene Autoleucel (BMS-986393), CC-95266,, GPRC5D CAR T cells
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Multiple Myeloma
06/27
06/32
CC-95266-MM-001, NCT04674813: A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma

Active, not recruiting
1
180
US
CC-95266, Fludarabine, Cyclophosphamide, Bendamustine
Juno Therapeutics, a Subsidiary of Celgene
Multiple Myeloma
06/25
06/25
NCT06121843: A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Recruiting
1
111
Canada, US
BMS-986393, CC-95266, Alnuctamab, BMS-986349, CC-93269, EM901, Mezigdomide, BMS-986348, CC-92480, Iberdomide, BMS-986382, CC-220
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Multiple Myeloma
08/28
08/28
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
arlocabtagene autoleucel (BMS-986393) / BMS
QUINTESSENTIAL-2, NCT06615479: A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma

Recruiting
3
440
Europe, Canada, Japan, US, RoW
BMS-986393, Cyclophosphamide, Fludarabine, Daratumumab, Pomalidomide, Dexamethasone, Carfilzomib
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, Celgene Corporation
Relapsed or Refractory Multiple Myeloma (RRMM)
12/27
07/32
QUINTESSENTIAL, NCT06297226: Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

Recruiting
2
175
Canada, Japan, US, RoW
Arlocabtagene Autoleucel (BMS-986393), CC-95266,, GPRC5D CAR T cells
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Multiple Myeloma
06/27
06/32
CC-95266-MM-001, NCT04674813: A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma

Active, not recruiting
1
180
US
CC-95266, Fludarabine, Cyclophosphamide, Bendamustine
Juno Therapeutics, a Subsidiary of Celgene
Multiple Myeloma
06/25
06/25
NCT06121843: A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Recruiting
1
111
Canada, US
BMS-986393, CC-95266, Alnuctamab, BMS-986349, CC-93269, EM901, Mezigdomide, BMS-986348, CC-92480, Iberdomide, BMS-986382, CC-220
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Multiple Myeloma
08/28
08/28

Download Options